MedTrace Logo

BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)

NCT00929851 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1199

Last updated 2021-10-29

No results posted yet for this study

Summary

a 48-week, 2-arm parallel group, "fixed combination" beclomethasone dipropionate plus formoterol fumarate versus formoterol in patients with severe chronic obstructive pulmonary disease

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

CHF1535

Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose

DRUG

Formoterol fumarate

Formoterol fumarate 12 µg per metered dose

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • Jadwiga A Wedzicha, MD, Prof · UCL MEDICAL SCHOOL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2012-03-31
Completion
2012-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00929851 on ClinicalTrials.gov